PreHevbrio: the first approved 3-antigen hepatitis B vaccine

References

• Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924–931. doi: 10.7326/0003-4819-66-5-924
   PubMed Web of Science ®Google Scholar
• Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int. 2013;33(1):164–175. doi: 10.1111/liv.12081
   PubMedGoogle Scholar
• Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR–16):1–33.
   PubMedGoogle Scholar
• Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on immunization Practices. MMWR Recomm Rep. 2018;67(1):1–31. doi: 10.15585/mmwr.rr6701a1
   PubMed Web of Science ®Google Scholar
• Chisari FV, Masanori I, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol. 2010;58(4):258–266. doi: 10.1016/j.patbio.2009.11.001
   PubMedGoogle Scholar
• Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000. doi: 10.1093/clinids/20.4.992
   PubMed Web of Science ®Google Scholar
• McKeating C, Cadden I, McDougall N, et al. Progression from acute to chronic hepatitis B is more common in older adults. Ulster Med J. 2018 Oct;87(3):177–180.
   PubMedGoogle Scholar
• Haber P, Schillie S, Hepatitis B. Pinkbook: HepatitisB – CDC. Available online at https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (accessed on Nov 3, 2022).
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Flores JE, Thompson AJ, Ryan M, et al. The global impact of hepatitis B vaccination on hepatocellular carcinoma. Vaccines (Basel). 2022;10(5):793. doi: 10.3390/vaccines10050793
   PubMed Web of Science ®Google Scholar
• Kim BH, Kim WR. Epidemiology of hepatitis B virus infection in the United States. Clin Liver Dis. 2018;12(1):1–4. doi: 10.1002/cld.732
   Google Scholar
• CDC 2021 Viral Hepatitis. 2019 Viral hepatitis surveillance report. Atlanta GA. US Department of Health and Human Services, CDC, https://www.cdc.gov/hepatitis/statistics/serveillanceRpts.htm
   Google Scholar
• Department of Health and Human Services 2022. Viral hepatitis in the United States: data and trends. Available at: http://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html#:~:text=After%20decades%20of%20declines%20in,%2C%20Tennessee%20and%20West%20Virginia). Accessed on Nov 3, 2022.
   Google Scholar
• European Centre for Disease Prevention and Control. Hepatitis B. In: ECDC. Annual epidemiological report for 2020. Stockholm: ECDC; 2022.
   Google Scholar
• WHO 2022. Hepatitis B. Available at https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed Nov 3, 2022.
   Google Scholar
• Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine. 2013;31(46):5300–5305. doi: 10.1016/j.vaccine.2013.05.068
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012;30(16):2689–2696. doi: 10.1016/j.vaccine.2012.02.001
   PubMed Web of Science ®Google Scholar
• Vesikari T, Langley JM, Segall N, et al. PROTECT study group immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases. 2021;21(9):1271–1281. doi: 10.1016/S1473-3099(20)30780-5
   PubMed Web of Science ®Google Scholar
• Fan W, Chen XF, Shen C, et al. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine. 2016;34(40):4835–4841. doi: 10.1016/j.vaccine.2016.08.027
   PubMed Web of Science ®Google Scholar
• Yang S, Tian G, Cui Y, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6(1):27251. doi: 10.1038/srep27251
   PubMedGoogle Scholar
• Schillie SF, Spradling PR, Murphy TV. Immune response of hepatitis B vaccine among persons with diabetes. Diabetes Care. 2012;35(12):2690–2697. doi: 10.2337/dc12-0312
   PubMed Web of Science ®Google Scholar
• Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 18-59 years: updated recommendations of the Advisory Committee on immunization Practices – United States, 2022. MMWR. 2022;71(13):477–483. doi: 10.15585/mmwr.mm7113a1
   PubMed Web of Science ®Google Scholar
• Yue X, Black CL, O’Halloran A, et al. Hepatitis a and hepatitis B vaccination coverage among adults with chronic liver disease. Vaccine. 2018;36(9):1183–1189. doi: 10.1016/j.vaccine.2018.01.033
   PubMed Web of Science ®Google Scholar
• Lu P-J, Hung M-C, Srivastav A, et al. Surveillance of vaccination coverage among adult populations – United States, 2018. MMWR. 2021;70(3):1–25. doi: 10.15585/mmwr.ss7003a1
   PubMedGoogle Scholar
• Diminsky D, Schirmbeck R, Reimann J, et al. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 1997;15(6–7):637–647. doi: 10.1016/S0264-410X(96)00239-3
   PubMed Web of Science ®Google Scholar
• Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in adults. Isr Med Assoc J. 2001;3(5):328–332.
   PubMed Web of Science ®Google Scholar
• Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985;228(4704):1195–1199. doi: 10.1126/science.2408336
   PubMed Web of Science ®Google Scholar
• Budkowska A, Dubreuil P, Capel F, et al. Hepatitis B virus pre-S gene-encoded antigenic specificity and anti-pre-S antibody: relationship between anti-pre-S response and recovery. Hepatology. 1986;6(3):360–368. doi: 10.1002/hep.1840060305
   PubMed Web of Science ®Google Scholar
• Yerushalmi B, Raz R, Blondheim O, et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in neonates. Pediatr Infect Dis J. 1997;16(6):587–592. doi: 10.1097/00006454-199706000-00009
   PubMed Web of Science ®Google Scholar
• Shouval D, Ilan Y, Adler R, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 1994;12(15):1453–1459. doi: 10.1016/0264-410X(94)90155-4
   PubMed Web of Science ®Google Scholar
• Madalinski K, Sylvan SPE, Hellström U, et al. Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B™ vaccine. Med Sci Monit. 2004;10(s1):I10–17.
   Google Scholar
• Hellström UB, Madalinski K, Sylvan SPE. PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen. J Virol. 2009;6(1):7. doi: 10.1186/1743-422X-6-7
   Google Scholar
• Sylvan SPE, Madalinski K, Hellström UB. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac™ vaccine. Vaccine. 2010;28(2):446–451. doi: 10.1016/j.vaccine.2009.10.023
   Web of Science ®Google Scholar
• PreHevbrio. Prescribing information. https://www.prehevbrio.com/wp-content/uploads/2021/11/PreHevbrio-Full-Prescribing-Information.pdf. Accessed on Nov 2, 2022.
   Google Scholar
• CDC. Thimerosal in vaccines: a joint statement of the American academy of pediatrics and the public health Services. MMWR Morb Mortal Wkly Rep. 1999;48(26):563–565.
   PubMedGoogle Scholar
• Shapira MY, Zeira E, Adler R, et al. Rapid seroprotection against hepatitis B following the first dose of a pre-S1/Pre-S2/S vaccine. J Hepatol. 2001;34(1):123–127. doi: 10.1016/S0168-8278(00)00082-9
   PubMed Web of Science ®Google Scholar
• Schumann A, Fiedler M, Dahmen U, et al. Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat. 2007;14(8):592–598. doi: 10.1111/j.1365-2893.2007.00848.x
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: a phase 3 randomized clinical trial. Vaccine. 2021;39(29):3892–3899. doi: 10.1016/j.vaccine.2021.05.067
   PubMed Web of Science ®Google Scholar
• Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179(2):489–492. doi: 10.1086/314578
   PubMed Web of Science ®Google Scholar
• Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the centers of disease Control multicenter efficacy trial among homosexual men. Ann Of Intern Med. 1982;97(3):362–366. doi: 10.7326/0003-4819-97-3-362
   PubMed Web of Science ®Google Scholar
• Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein – a preliminary study on immunogenicity. Vaccine. 1992;10(7):439–442. doi: 10.1016/0264-410X(92)90391-V
   PubMed Web of Science ®Google Scholar
• Hourvitz A, Mosseri R, Solomon A, et al. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing pre S antigens: a preliminary report. J Viral Hepatitis. 1996;3(1):37–42. doi: 10.1111/j.1365-2893.1996.tb00079.x
   PubMed Web of Science ®Google Scholar
• Yap I, Guan R, Chan SH. Study on the Comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol. 1995;10(1):51–55. doi: 10.1111/j.1440-1746.1995.tb01047.x
   PubMed Web of Science ®Google Scholar
• Esaulenko EV, Yakovlev AA, Volkov GA, et al. Efficacy and safety of a 3-antigen (pre-S1/Pre-S2/S) hepatitis B vaccine: results of a phase 3 randomized clinical trial in the Russian Federation. Clin Infect Dis. 2021;73(9):e3333–e3339. doi: 10.1093/cid/ciaa1649
   PubMed Web of Science ®Google Scholar
• Atsmon J, Machluf N, Yayon-Gur V, et al. Rapid and high seroprotection rates achieved with a tri-antigenic hepatitis B vaccine in healthy young adults: results from a phase IV study. Vaccine. 2021;39(8):1328–1332. doi: 10.1016/j.vaccine.2020.12.050
   PubMed Web of Science ®Google Scholar
• Vesikari T, Finn A, Vac Damme P, et al. Immunogenicity and safety of a 3-antigen hepatitis b vaccine vs a single-antigen hepatitis B vaccine – a phase 3 randomized clinical trial. JAMA Netw Open. 2021;4(10):e2128652. doi: 10.1001/jamanetworkopen.2021.28652
   PubMed Web of Science ®Google Scholar
• Donken R, de Melker HE, Rots NY, et al. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine. 2015;33(12):1426–1432. doi: 10.1016/j.vaccine.2015.01.072
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Healthy people 2030 objectives–vaccination 2021 [1 Jul 2021]. Available from: https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination
   Google Scholar
• Alon D, Stein GY, Hadas-Golan V, et al. Immunogenicity of Sci-B-Vac (a third-generation hepatitis B vaccine) in HIV-Positive adults. Isr Med Assoc J. 2017;19(3):143–146.
   PubMed Web of Science ®Google Scholar
• Etzion O, Novack V, Perl Y, et al. Sci-B-Vac vs ENGERIX- B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial. J Crohns Colitis. 2016;10(8):905–912. doi: 10.1093/ecco-jcc/jjw046
   PubMed Web of Science ®Google Scholar
• Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004;97(2):c67-c–72. doi: 10.1159/000078403
   Google Scholar
• Elhanan E, Boaz M, Schwartz I, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B- Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2017;22(1):151–158. doi: 10.1007/s10157-017-1416-7
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. In Us department of health and human services, food and drug administration, center for drug evaluation and research, center for biologics evaluation and research: 10. (available at: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials | FDA; Accessed Nov 3, 2022; Rockville MD: Jeffrey Shuren; 2007.
   Google Scholar
• Vesikari T, Langley JM, Spaans J, et al. The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen HBV vaccine. Vaccine. 2023;41(24):3584–3588. doi: 10.1016/j.vaccine.2023.05.010
   PubMed Web of Science ®Google Scholar
• Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005;41(6):1383–1390. doi: 10.1002/hep.20716
   PubMed Web of Science ®Google Scholar
• Walayat S, Ahmed Z, Martin D, et al. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7(24):2503–2509. doi: 10.4254/wjh.v7.i24.2503
   PubMed Web of Science ®Google Scholar
• Janssen JM, Jackson S, Heyward WL, et al. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age. Vaccine. 2015;33(31):3514–3618. doi: 10.1016/j.vaccine.2015.05.070
   Web of Science ®Google Scholar